SINGAPORE: Medical diagnostic company Restalyst has launched a new gastric cancer screening kit that is more accurate, the National University of Singapore (NUS) announced on Wednesday (Nov 11).
The kit, known as GC-REAAD, is a blood-based test that that has demonstrated a better ability to detect without false positives compared to other tests. Validation studies were conducted on patient samples collected by the Singapore Gastric Cancer Consortium.
The test was developed from technology invented by Asst Prof Lim Yoon Pin from the Department of Biochemistry, NUS Yong Loo Lin School of Medicine. Dr Lim's team managed to identify a protein that is expressed at significantly higher levels in gastric cancer patients compared to patients without gastric cancer.
"We are delighted that Restalyst has successfully commercialised this NUS technology, translating it from a technology on a lab bench, into a diagnostic tool that can screen for gastric cancer. This is a good example of one of our local SMEs bringing new technologies from NUS to market and boosting their own competitiveness," said Dr Lily Chan, CEO of NUS Enterprise.